Silence Therapeutics/$SLN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Silence Therapeutics
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Ticker
$SLN
Sector
Primary listing
Employees
116
Headquarters
Website
SLN Metrics
BasicAdvanced
$323M
-
-$1.36
1.34
-
Price and volume
Market cap
$323M
Beta
1.34
52-week high
$7.78
52-week low
$1.97
Average daily volume
188K
Financial strength
Current ratio
7.689
Quick ratio
7.156
Long term debt to equity
0.131
Total debt to equity
0.246
Profitability
EBITDA (TTM)
-69.405
Gross margin (TTM)
91.32%
Net profit margin (TTM)
-249.86%
Operating margin (TTM)
-270.95%
Effective tax rate (TTM)
-0.52%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-23.40%
Return on equity (TTM)
-64.30%
Valuation
Price to revenue (TTM)
12.569
Price to book
4.36
Price to tangible book (TTM)
5.11
Price to free cash flow (TTM)
-4.473
Free cash flow yield (TTM)
-22.36%
Free cash flow per share (TTM)
-1.527
Growth
Revenue change (TTM)
40.39%
Earnings per share change (TTM)
-18.30%
3-year revenue growth (CAGR)
5.97%
10-year revenue growth (CAGR)
133.43%
3-year earnings per share growth (CAGR)
-5.01%
10-year earnings per share growth (CAGR)
9.46%
SLN News
AllArticlesVideos
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Business Wire1 week ago
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Business Wire3 weeks ago
Silence Therapeutics to Participate in September Investor Conferences
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Silence Therapeutics stock?
Silence Therapeutics (SLN) has a market cap of $323M as of November 16, 2025.
What is the P/E ratio for Silence Therapeutics stock?
The price to earnings (P/E) ratio for Silence Therapeutics (SLN) stock is 0 as of November 16, 2025.
Does Silence Therapeutics stock pay dividends?
No, Silence Therapeutics (SLN) stock does not pay dividends to its shareholders as of November 16, 2025.
When is the next Silence Therapeutics dividend payment date?
Silence Therapeutics (SLN) stock does not pay dividends to its shareholders.
What is the beta indicator for Silence Therapeutics?
Silence Therapeutics (SLN) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.